Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 154.65% | -86.95% | 231.78% | -26.84% | -361.63% |
| Total Depreciation and Amortization | 204.34% | 391.90% | 342.83% | 259.07% | 68.43% |
| Total Amortization of Deferred Charges | -4.24% | -4.24% | -2.54% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -48.31% | -26.32% | -172.34% | 426.59% | -39.96% |
| Change in Net Operating Assets | -131.83% | 26.93% | 504.24% | -993.35% | 878.80% |
| Cash from Operations | -100.29% | -101.75% | 364.76% | -1,340.58% | 400.31% |
| Capital Expenditure | -- | 65.48% | 79.59% | 100.00% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 99.99% | -7,375.00% | 81.63% | -224,640.00% | -65,679.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -962.50% | 37.50% | -2,961.80% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -100.00% | 6.01% | -- |
| Repurchase of Common Stock | -347.22% | 88.20% | 99.83% | -20.31% | 98.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,096.08% | 211.34% | 123.62% | 132.84% | 89.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.15% | -18.79% | 2,018.20% | -135.94% | -1,044.95% |